Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16718949 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2BRD4TP53ALDH1A1POLB | |
| SCHEMBL10049180 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2BRD4TP53ALDH1A1POLB | |
| SCHEMBL10049540 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2BRD4TP53ALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL27483811 | 0.98 | SMN1; SMN2 (0.49) | SMN1; SMN2BRD4TP53ALDH1A1POLB | |
| Iodide SCHEMBL10383845 | 0.98 | SMN1; SMN2 (0.49) | SMN1; SMN2BRD4TP53ALDH1A1POLB | |
| SCHEMBL18434254 | 0.94 | SMN1; SMN2 (0.53) | SMN1; SMN2BRD4TP53ALDH1A1POLB | |
| SCHEMBL14712106 | 0.88 | TP53 (0.52) | SMN1; SMN2BRD4TP53ALDH1A1POLB | |
| SCHEMBL7853872 | 0.88 | TP53 (0.52) | SMN1; SMN2BRD4TP53ALDH1A1POLB | |
| SCHEMBL14711275 | 0.88 | TP53 (0.52) | SMN1; SMN2BRD4TP53ALDH1A1POLB | |
| Tert-Butyl Formate SCHEMBL27675054 | 0.85 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2996 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4392137-A1 | COMBINATION THERAPIES | Versanis Bio, Inc. (US) | 2024-07-03 | — | — | EP | claimed |
| US-20240024365-A1 | POTENTIATION OF BONE MARROW CELL ACTIVITY BY COADMINISTRATION WITH OXYTOCIN | CREATIVE MEDICAL TECHNOLOGIES, INC. (US) | 2024-01-25 | — | — | US | claimed |
| US-20240009249-A1 | ADIPOGENIC CELL COMPOSITIONS AND METHODS | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2024-01-11 | — | — | US | claimed |
| CN-113750117-B | Adipose tissue essence prepared from liposuction waste liquid, and preparation method and application thereof | 成都世联康健生物科技有限公司 | 2024-01-09 | — | — | CN | claimed |
| EP-4251175-A1 | ADIPOGENIC CELL COMPOSITIONS AND METHODS | Flagship Pioneering, Inc. (US) | 2023-10-04 | — | — | EP | claimed |
| US-11766471-B2 | Compositions and methods for induced brown fat differentiation | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-09-26 | — | — | US | claimed |
| US-20230293598-A1 | PREVENTION OF RADIATION EXPOSURE ASSOCIATED PATHOLOGY BY TREATMENT WITH UMBILICAL CORD DERIVED REGENERATIVE CELLS | Narkeshyo LLC (US) | 2023-09-21 | — | — | US | claimed |
| US-20230266346-A1 | METHODS FOR QUANTIFYING POTENCY OF REGENERATIVE IMMUNOTHERAPIES | CREATIVE MEDICAL TECHNOLOGIES, INC. (US) | 2023-08-24 | — | — | US | claimed |
| US-20230241093-A1 | TARGETING ADISPSIN FOR NONALCOHOLIC STEATOHEPATITIS (NASH)- INDUCED LIVER FIBROSIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-08-03 | — | — | US | claimed |
| WO-2023141525-A2 | ACTRII ANTIBODY TREATMENTS | VERSANIS BIO, INC. (US) | 2023-07-27 | — | — | WO | claimed |
| WO-1994003614-A1 | INHIBITOR RESISTANT SERINE PROTEASES | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1994-02-17 | — | — | WO | claimed |
| US-5223425-A | DNA encoding human adipsin with complement D activity | THE BETH ISRAEL HOSPITAL ASSOCIATION (US) | 1993-06-29 | — | — | US | claimed |
| EP-0287509-B1 | DIAGNOSING OBESITY CAUSED BY A GENETIC ABNORMALITY AND METHOD OF THERAPEUTICALLY TREATING GENETICALLY CAUSED OBESITY | THE BETH ISRAEL HOSPITAL ASSOCIATION (US) | 1992-09-16 | — | — | EP | claimed |
| EP-0382720-B1 | DIAGNOSING OBESITY CAUSED BY A GENETIC ABNORMALITY AND METHOD OF THERAPEUTICALLY TREATING GENETICALLY CAUSED OBESITY | THE BETH ISRAEL HOSPITAL ASSOCIATION (US) | 1992-09-09 | — | — | EP | claimed |
| WO-1992006104-A1 | ADIPOCYTE-SPECIFIC DNA SEQUENCES AND USE FOR THE PRODUCTION OF TRANSGENIC ANIMALS EXHIBITING ALTERED FAT METABOLISM | THE DANA-FARBER CANCER INSTITUTE (US) | 1992-04-16 | — | — | WO | claimed |
| EP-0382720-A4 | DIAGNOSING OBESITY CAUSED BY A GENETIC ABNORMALITY AND METHOD OF THERAPEUTICALLY TREATING GENETICALLY CAUSED OBESITY | — | 1991-01-02 | — | — | EP | claimed |
| EP-0382720-A1 | DIAGNOSING OBESITY CAUSED BY A GENETIC ABNORMALITY AND METHOD OF THERAPEUTICALLY TREATING GENETICALLY CAUSED OBESITY. | BETH ISRAEL HOSPITAL (US) | 1990-08-22 | — | — | EP | claimed |
| WO-1990006365-A1 | RECOMBINANT PROTEINS WITH ADIPSIN AND COMPLEMENT D ACTIVITIES | THE BETH ISRAEL HOSPITAL ASSOCIATION (US) | 1990-06-14 | — | — | WO | claimed |
| EP-0287509-A1 | Diagnosing obesity caused by a genetic abnormality and method of therapeutically treating genetically caused obesity | THE BETH ISRAEL HOSPITAL ASSOCIATION (US) | 1988-10-19 | — | — | EP | claimed |
| WO-1988007681-A1 | DIAGNOSING OBESITY CAUSED BY A GENETIC ABNORMALITY AND METHOD OF THERAPEUTICALLY TREATING GENETICALLY CAUSED OBESITY | THE BETH ISRAEL HOSPITAL ASSOCIATION (US) | 1988-10-06 | — | — | WO | claimed |